24/7 Market News Snapshot 11 July, 2025 – Cel-Sci Corporation (NYSE:CVM)
DENVER, Colo., 11 July, 2025 (www.247marketnews.com) – (NYSE:CVM) are discussed in this article.
Cel-Sci Corporation (CVM) is experiencing significant momentum, marked by a notable 65.31% increase in its stock price, rising from $3.82 to $6.315 amid active trading with over 5.32 million shares exchanged today. This surge reflects heightened investor interest, prompting anticipation regarding potential catalysts that may continue to drive this volatility.
In an equally transformative development, Cel-Sci is thrilled to announce a strategic partnership with a prominent pharmaceutical company, aimed at advancing the regulatory and commercial trajectory of its revolutionary cancer immunotherapy, Multikine* (Leukocyte Interleukin, Injection). This agreement is expected to facilitate the application for Breakthrough Medicine Designation, which could receive regulatory approval within a streamlined 60-day window.
Multikine has shown considerable efficacy in treating newly diagnosed head and neck cancer patients, boasting a five-year survival rate of 73% in clinical trials, a marked improvement over the 45% rate associated with standard treatments. The new partnership is strategically aligned with regional healthcare initiatives under Vision 2030, which aim to strengthen biotechnology infrastructure and enhance healthcare solutions.
By collaborating with local expertise, Cel-Sci aims to leverage market insights and established networks, effectively expediting the regulatory approval process and optimizing distribution for Multikine. The company has garnered interest from significant local investment funds eager to engage in potential joint ventures addressing pressing medical needs in the area.
Geert Kersten, CEO of Cel-Sci, expressed confidence in Multikine’s readiness to fulfill the rigorous requirements for Breakthrough Medicine Designation. This partnership represents a pivotal moment in Cel-Sci’s commitment to innovation, further positioning the company as a leader in the advancement of cancer treatment and in paving the way for improved patient outcomes globally.